Products for Research Use Only
RegisterLogin

Brigimadlin

CAT: 0804-HY-152859-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-152859-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Brigimadlin (BI 907828) is an orally active E3 ubiquitin-protein ligase MDM-2 inhibitor, preventing MDM-2 from negatively regulating the tumor suppressor p53. Brigimadlin can be used for antineoplastic research[1][2][3][4].
CAS Number
2095116-40-6
Product Name Alternative
BI 907828
UNSPSC
12352005
Hazard Statement
H300, H360, H372, H413
Target
E1/E2/E3 Enzyme; MDM-2/p53
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/brigimadlin.html
Purity
99.88
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
OC(C1=C(C)C2=NN([C@@]([C@]3([H])C4)([H])[C@H](C5=C(C(Cl)=CC=C5)F)[C@@]6(C7=CC=C(Cl)C=C7NC6=O)N3CC8CC8)C4=C2C=C1)=O
Molecular Formula
C31H25Cl2FN4O3
Molecular Weight
591.46
Precautions
H300, H360, H372, H413
References & Citations
[1]Gollner Andreas, et al. Preparation of spiroindolepyrrolidinone derivatives for use as MDM2-p53 inhibitors: World Intellectual Property Organization, WO2017060431. 2017-04-13.|[2]WHO Drug Information-World Health Organization (WHO) .|[3]Hao X, et al. BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models. Neuro Oncol. 2023 May 4;25 (5) :913-926.|[4]Yoo C, et al. Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors. Future Oncol. 2024 Jan 12.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3

Alternative Products

CatalogName
C01703-100mgBrigimadlin

Popular Products